Mineralys Therapeutics Reports P-II (Target-HTN) Trial Results of MLS-101 for Uncontrolled and Resistant Hypertension
Shots:
- The P-II (Target-HTN) trial evaluated MLS-101 (50/100mg, qd) as an add-on therapy to stable background treatment of ≥2 antihypertensive agents vs PBO in 200 male and female patients aged ≥18yrs. with uncontrolled & resistant hypertension
- The trial met its 1EPs & 2EPs i.e., reduction in systolic blood pressure (SBP) at 12.5/50/100mg of 1.4/9.7/7.9mmHg, patients used a Thiazide Diuretic showed a mean PBO-adjusted reduction in SBP of 5.3/13.2/11.4mmHg. The therapy was well tolerated with no notable effects on serum cortisol & a modest increase and rapid reversibility of serum potassium
- MLS-101 is a highly selective aldosterone synthase inhibitor (licensed from Mitsubishi Tanabe Pharma Corporation) & was indicated for hypertension
Ref: PR Newswire | Image: Mineralys
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
